|
|
Article: Bellwether Report Issues Alert For Celgene Corporation.
- Article from:
- M2 Presswire
- Article date:
- April 27, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-27 April 2006-bellwetherreport.com: Bellwether Report Issues Alert For Celgene Corporation(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:27042006
The Bellwether Report Takes Notice Of Celgene Corp. (Nasdaq:CELG) A terror from the past has provided hope in the present. Celgene's flagship product THALOMID treats a type of leprosy; it is a form of thalidomide, a sedative and morning sickness therapy used in Europe in the late 1950s until it was linked to birth defects and pulled from the market in 1961. The company develops drugs primarily to treat inflammatory diseases and cancer. THALOMID is in clinical trials to determine its usefulness in ...